抗脂 (休斯) 综合征40周年纪念日
1Department of Rheumatology, Royal London Hospital, London, UK.
Lupus
|December 8, 2023
概括
这篇文章庆祝了治疗自身免疫多分泌综合征 (APS) 40年的进展. 早期诊断和有效的治疗方法显著改善了这种罕见疾病患者的生活质量.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 自免疫多分泌综合征 (APS) 影响大约2000人中的1人.
- 这种情况涉及到对多个内分泌腺体的自身免疫性攻击.
- 从历史上看,APS在患者管理方面提出了重大挑战.
研究的目的:
- 为了纪念在APS理解和治疗方面取得重大进展的40周年.
- 突出早期诊断和治疗干预措施的影响.
- 为了强调四十年来患者生活质量的改善.
主要方法:
- 对APS患者的历史数据和临床结果的审查.
- 40年来诊断进步和治疗疗效的分析.
- 对患者生活质量指标的纵向评估.
主要成果:
- 对患有APS的患者来说,生活质量的显著改善.
- 早期诊断在缓解疾病进展方面取得的成功.
- 有效的治疗策略已成为护理的标准.
- 增加生存率和减少长期并发症.
结论:
- 在过去的40年里,在管理APS方面取得了变革性的进展.
- 持续专注于早期检测和个性化治疗至关重要.
- 进一步的研究可以建立在这些成功的基础上,以提高患者的治疗结果.
相关概念视频
Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187


